Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2: I. Effects of some formulation parameters on microparticle characteristics

Journal of Microencapsulation

Volumn 28, Issue 6, 2011, Pages 582-594

  Devrim, Burcu ^a   Bozkír, Asuman ^a   Canefe, Kandemir ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Immunotherapy; Interleukin 2; Lung cancer; Microparticles; Poly(lactic co glycolic acid)

Indexed keywords

DICHLOROMETHANE; DRUG CARRIER; POLYGLACTIN; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SCREENING; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; LUNG; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SOLVENT EXTRACTION; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-2; LACTIC ACID; LUNG; LUNG NEOPLASMS; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTEIN STABILITY; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 80051751265     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.599438     Document Type: Article

References (46)

1. Abbas AK, Lichtman AH, Pober JS. 2000. Cellular and molecular immunology. 4th ed. Philadelphia, PA, USA: Saunders Company.
2. Ahmed H. 2005. Electrophoretic analyses of protein. In: Principles and reactions of protein extraction. Purification and characterization. Boca Raton, FL: CRC Press, Chapter 3, pp. 71-131.
3. Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces, 2009;72(1):48-56.
4. Aubert-Pouessel A, Venier-Julienne M-C, Clavreul A, Sergent M, Jollivet C, Montero-Menei CN, Garcion E, Bibby DC, Menei P, Benoit J-P. In vitro study of GDNF release from biodegradable PLGA microspheres. J Controlled Release, 2004;95:463-75. (Pubitemid 38340497)
5. Barakat NS, Radwan MA. In vitro performance of carbamazepine loaded to various molecular weights of poly(d, l-lactide-co-glycolide). Drug Deliv, 2006;13:9-18. (Pubitemid 43087615)
6. Bernsen MR, Tang J-W, Everse LA, Koten JW, Den Otter W. Interleukin 2 (IL-2) therapy: Potential advantages of locoregional versus systemic administration. Cancer Treat Rev, 1999;25:73-82. (Pubitemid 29353667)
7. Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: Influence of the encapsulation technique and polymer purity on micro-spheres characteristics. Eur J Pharm Biopharm, 1998;45:295-305. (Pubitemid 28270818)
8. Boury F, Marchais H, Proust JE, Benoit JP. Bovine serum albumin release from poly(alpha-hydroxy acid) microspheres: Effects of polymer molecular weight and surface properties. J Controlled Release, 1997;45:75-86. (Pubitemid 27055795)
9. Cadée JA, De Groot CJ, Jiskoot W, Den Otter W, Hennink WE. Release of recombinant human interleukin-2 from dextran-based hydrogels. J Controlled Release, 2002;78:1-13. (Pubitemid 34081848)
10. Cegnar M, Kos J, Julijana Kristl J. Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: Development and fundamental studies on preservation of its activity. Eur J Pharm Sci, 2004;22:357-64. (Pubitemid 38953894)
11. Chen H, Yang W, Chen H, Liu L, Gao F, Yang X, Jiang Q, Zhang Q, Wang Y. Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan. Colloids Surf B, 2009;73:212-18.
12. Curatolo L, Valsas|na B, Caccia C, Raimondi GL, Orsini G, Bianchetti A. Recombinant human IL-2 is cytotoxic to oligodendrocytes after in vitro self aggregation. Cytokine, 1997;9(10):734-9. (Pubitemid 27477716)
13. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM, Koten JW. Local therapy of cancer with free IL-2. Cancer Immunol Immunother, 2008;57:931-50.
14. Devrim B, Bozk|r A, Canefe K. 2009. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of recombinant human interleukin-2 microparticles, Proceedings of the 36th Annual & Exposition of the Controlled Release Society, Copenhagen-Denmark, July 18-22.
15. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, Nagai T. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Controlled Release, 2006;112:35-42.
16. Fiedler W, Jasmin C, De Mulder PH, Pyrhonen S, Palmer PA, Franks CR, Oskam R, Hossfeld DK. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer, 1992;28(2-3):443-6.
17. Florindo HF, Pandit S, Lacerda L, Goncalves LMD, Alpar HO, Almeida AJ. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-3-caprolactone-based nanoparticles. Biomaterials, 2009;30:879-91.
18. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microspheres preparation process technology. J Controlled Release, 2005;102:313-32. (Pubitemid 40093756)
19. Freytag T, Dashevsky A, Tillman L, Hardee GE, Bodmeier R. Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microsphers. J Controlled Release, 2000;69:197-207.
20. Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm, 2008;350:14-26.
21. Holst-Hansen C, Brünner N. 1998. MTT-cell proliferation assay. In: Celis JE, editor. Cell biology. A laboratory handbook. San Diego, CA: Academic Press, pp. 16-18.
22. Jeon H-J, Jeong Y-I, Jang M-K, Park Y-H, Nah J-W. Effect of solvent on the preparation of surfactant-free poly(lactide-co-glycolide) nanoparticles and norfloxacin release characteristics. Int J Pharm, 2000;207:99-108.
23. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer, 1997;79(7):1409-21. (Pubitemid 27143249)
24. Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, Kolitz JE. Bradley EC. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res, 1990;50:2009-17.
25. Leonardi D, Salomón CJ, Lamas MC, Olivieri AC. Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks. Int J Pharm, 2009;367:140-7.
26. Li X, Zhang Y, Yan R, Jia W, Yuan M, Deng X, Huang Z. Influence of process parameters on the protein stability encapsulated in poly-dl-lactide- poly(ethylene glycol) microspheres. J Controlled Release, 2000;68:41-52. (Pubitemid 30407060)
27. Maher SG, Condron CEM, Bouchier-Hayer DJ, Toomey DM. Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD). Clin Exp Immunol, 2005;139:279-86. (Pubitemid 40222845)
28. Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of wow process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm, 2007;334:137-48. (Pubitemid 46400322)
29. Matanić D, Beg-Zec Z, Stojanović D, Matakorić- Mileusnić N, Flego V, Milevoj-Ribić F. Cytokines in patients with lung cancer. Scand J Immunol, 2003;57:173-8. (Pubitemid 36232885)
30. Meng FT, Ma GH, Qiu W, Su ZG. W/O/W double emulsion technique using ethyl acetate as organic solvent: Effects of its diffusion rate on the characteristics of microparticles. J Controlled Release, 2003;91:407-16. (Pubitemid 36976770)
31. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Controlled Release, 2007;119:77-85. (Pubitemid 46561546)
32. Nguyen T, Wang R, Russell JH. IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol, 2000;30:1445-52. (Pubitemid 30311975)
33. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol, 1990;8(10):1650-6. (Pubitemid 20334319)
34. Physician's Desk Reference (PDR), 61st ed. 2007. Montvale, NJ: Thomson PDR.
35. Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J Controlled Release, 2008;128:224-32.
36. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst, 1994;86(15):1159-66. (Pubitemid 24249302)
37. Ruan G, Feng S-S, Li Q-T. Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J Controlled Release, 2002;84:151-60. (Pubitemid 35439142)
38. Sahana DK, Mittal G, Bhardwaj V, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci, 2008;97(4):1530-42.
39. Spiers ID, Alpar HO, Eyles JE, Bozkir A, Miller J, Williamson ED. Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis. J Pharm Pharmacol, 1999;51:991-7. (Pubitemid 29462385)
40. Thomas TT, Kohane DS, Wang A, Langer R. Microparticulate formulations for the controlled release of interleukin-2. J Pharm Sci, 2004;93(5):1100-9. (Pubitemid 38529684)
41. Vladisavljevi'c GT, Schubert H. Influence of process parameters on droplet size distribution in SPG membrane emulsification and stability of prepared emulsion droplets. J Membr Sci, 2003;225:15-23. (Pubitemid 37371922)
42. θ subsets. Cell Immunol, 1997;182:152-60. (Pubitemid 28134002)
43. Yang Y-Y, Chung T-S, Ng NP. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials, 2001;22:231-41.
44. Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res, 2004;27(1):1-12. (Pubitemid 43158226)
45. Yin J, Noda Y, Yotsuyanagi T. Properties of poly(lactic-co-glycolic acid) nanospeheres containing protease inhibitors: Camostat mesilate and nafamostat mesilate. Int J Pharm, 2006;314:46-55.
46. Zhao J, Liu C-S, Yuan Y, Tao X-Y, Shan X-Q, Sheng Y, Wu F. Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers. Biomaterials, 2007;28:1414-22. (Pubitemid 44959037)